Valuation: Cerenis Therapeutics

Market Cap 66.07M 75.6M 61.08M 56.43M 106M 7.26B 108M 728M 286M 3.56B 284M 278M 12.24B P/E 2026 *
-4.03x
P/E 2027 * -6.32x
Enterprise Value 71.87M 82.24M 66.44M 61.38M 116M 7.9B 118M 792M 311M 3.87B 309M 302M 13.32B EV / Sales 2026 *
15.4x
EV / Sales 2027 * 5.1x
Free-Float
82.07%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 49 2019-09-05
Director of Finance/CFO - -
Chief Operating Officer - 2005-12-31
Director TitleAgeSince
Director/Board Member 49 2019-09-05
Director/Board Member 52 2010-07-19
Director/Board Member 76 2015-02-05
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 75.25M
+6.05%+7.79%+62.23%+88.46% 53.54B
+0.21%-6.28%+56.18%+127.90% 54.18B
+0.89%-2.42%+8.07%+434.51% 23.66B
+0.37%-4.13%-18.56%-16.48% 22.78B
+2.36%+3.86%+42.80%-6.60% 19.54B
-2.29%-1.92%+35.57%-29.14% 17.82B
-4.00%-10.96%+181.91%+328.17% 16.01B
-1.15%-3.07%+45.33%+654.85% 15.37B
-0.48%-2.30%+22.36%+187.62% 14.09B
Average +0.20%-1.83%+48.43%+196.59% 26.33B
Weighted average by Cap. +1.19%-0.61%+48.69%+164.08%

Financials

2026 *2027 *
Net sales 4.66M 5.33M 4.31M 3.98M 7.49M 512M 7.63M 51.37M 20.15M 251M 20.03M 19.59M 864M 14.72M 16.84M 13.6M 12.57M 23.67M 1.62B 24.1M 162M 63.66M 792M 63.26M 61.86M 2.73B
Net income -19.83M -22.69M -18.33M -16.93M -31.89M -2.18B -32.47M -219M -85.76M -1.07B -85.22M -83.34M -3.67B -12.92M -14.79M -11.95M -11.04M -20.78M -1.42B -21.16M -142M -55.89M -695M -55.54M -54.31M -2.39B
Net Debt 5.8M 6.64M 5.36M 4.95M 9.33M 637M 9.5M 63.94M 25.09M 312M 24.93M 24.38M 1.07B 9M 10.3M 8.32M 7.69M 14.48M 989M 14.74M 99.22M 38.93M 484M 38.68M 37.83M 1.67B
Logo Cerenis Therapeutics
ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases. At the end of 2025, the company boasted a portfolio of 3 products in clinical development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.872EUR
Average target price
10.50EUR
Spread / Average Target
+460.90%

Annual profits - Rate of surprise